KEGG   DRUG: Loncastuximab tesirine
Entry
D11338                      Drug                                   
Name
Loncastuximab tesirine (USAN);
Loncastuximab tesirine (genetical recombination) (JAN);
Loncastuximab tesirine-lpyl;
Zynlonta (TN)
Product
ZYNLONTA (ADC Therapeutics America)
Formula
C6544H10048N1718O2064S52
Exact mass
147387.9585
Mol weight
147479.4541
Remark
ATC code: L01FX22
Product: D11338<US>
Efficacy
Antineoplasitc, Anti-CD19 antibody
  Disease
Diffuse large B-cell lymphoma not otherwise specified [DS:H02434]
  Type
Antibody-drug conjugate
Comment
Treatment of hematological cancers
Target
CD19 [HSA:930] [KO:K06465]
  Pathway
hsa04151  PI3K-Akt signaling pathway
hsa04640  Hematopoietic cell lineage
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX22 Loncastuximab tesirine
      D11338  Loncastuximab tesirine (USAN) <US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Loncastuximab Tesirine
    D11338  Loncastuximab tesirine (USAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD19
     D11338  Loncastuximab tesirine (USAN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11338
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11338
Other DBs
CAS: 1879918-31-6
PubChem: 384585316
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system